143 related articles for article (PubMed ID: 38887335)
1. When Blood Cell Counts Matter: Hypereosinophilic Syndrome as a Rare Cause of Ischemic Strokes.
Kaur G; Rodriguez W; Ganev Y; Singh D; Awad A; Orozco L; Overberg R; Edgell RC
Cureus; 2024 May; 16(5):e60557. PubMed ID: 38887335
[TBL] [Abstract][Full Text] [Related]
2. Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report.
Yamamoto M; Ikuta K; Toki Y; Hatayama M; Shindo M; Torimoto Y; Okumura T
Medicine (Baltimore); 2017 Sep; 96(36):e8001. PubMed ID: 28885361
[TBL] [Abstract][Full Text] [Related]
3. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
Li B; Zhang GS; Dai CW; Pei MF
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
[TBL] [Abstract][Full Text] [Related]
4. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
5. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C
Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698
[TBL] [Abstract][Full Text] [Related]
7. FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.
Tennenbaum J; Groh M; Venditti L; Campos-Gazeau F; Chalayer E; De Broucker T; Hamidou M; Hunault M; Lyoubi A; Meunier R; Muron T; Sène D; Slama B; Guidoux C; Lefèvre G; Kahn JE; Denier C; Rohmer J
Stroke; 2021 Oct; 52(10):e605-e609. PubMed ID: 34304603
[TBL] [Abstract][Full Text] [Related]
8. [Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome].
Zhang GS; Li B; Pei MF; Dai CW; Zheng WL; Shen JK
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1541-4. PubMed ID: 15500716
[TBL] [Abstract][Full Text] [Related]
9. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
Stone RM; Gilliland DG; Klion AD
Semin Oncol; 2004 Apr; 31(2 Suppl 6):12-7. PubMed ID: 15175999
[TBL] [Abstract][Full Text] [Related]
11. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
[TBL] [Abstract][Full Text] [Related]
12. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract][Full Text] [Related]
13. The Spectrum of Hypereosinophilia and Associated Clonal Disorders - A Real-World Data Based on Combined Retrospective and Prospective Analysis from a Tropical Setting.
Sreedharanunni S; Varma N; Sachdeva MUS; Naseem S; Malhotra P; Bansal D; Trehan A; Varma S
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018052. PubMed ID: 30210745
[TBL] [Abstract][Full Text] [Related]
14. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.
Khoury P; Desmond R; Pabon A; Holland-Thomas N; Ware JM; Arthur DC; Kurlander R; Fay MP; Maric I; Klion AD
Allergy; 2016 Jun; 71(6):803-10. PubMed ID: 26797802
[TBL] [Abstract][Full Text] [Related]
15. Detection of FIP1L1-PDGFRA fusion gene-positive cells in the skin lesion of a patient with hypereosinophilic syndrome.
Kitayama S; Makino T; Yoto A; Mori S; Furukawa F; Torai R; Mizawa M; Shimizu T
Clin Exp Dermatol; 2023 Mar; 48(4):364-367. PubMed ID: 36763740
[TBL] [Abstract][Full Text] [Related]
16. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
17. Hypereosinophilic syndrome and proliferative diseases.
Ionescu MA; Wang L; Janin A
Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
[TBL] [Abstract][Full Text] [Related]
18. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
[TBL] [Abstract][Full Text] [Related]
19. [Hypereosinophilic syndromes: pathogenic and therapeutic up-to-date].
Kahn JE; Grandpeix-Guyodo C; Ackermann F; Charles P; Legrand F; Blétry O
Rev Med Interne; 2010 Apr; 31(4):268-76. PubMed ID: 20303627
[TBL] [Abstract][Full Text] [Related]
20. [Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome].
Zhang Y; Yu MH; Xu SC; Yang L; Yu Y; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):3-8. PubMed ID: 18512307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]